Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | FABP4 | P15090 | 2/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | LYN | P07948 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | FLT4 | P35916 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | BLK | P51451 | 1/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3581872 | 0.93 | CNR1 (0.41) | CNR1GRIK1DHODHMEN1KMT2A | |
| SCHEMBL3573189 | 0.90 | CNR1 (0.43) | CNR1FABP4KDRABL1NTRK1 | |
| SCHEMBL3581506 | 0.89 | MAPT (0.43) | KDRABL1NTRK1LCKFYN | |
| SCHEMBL3577192 | 0.88 | KDM4E (0.40) | CNR1KDRMEN1KMT2AMAPT | |
| SCHEMBL3573050 | 0.87 | GRIK1 (0.41) | CNR1KDRGRIK1MEN1KMT2A | |
| SCHEMBL3582672 | 0.86 | DGAT1 (0.42) | KDRKITFLT3RAB9AP2RY1 | |
| SCHEMBL3580763 | 0.86 | PSEN1 (0.45) | KDRABL1NTRK1LCKFYN | |
| SCHEMBL1463065 | 0.86 | P2RY1 (0.45) | GRIK1DHODHMEN1KMT2AMAPT | |
| SCHEMBL3573627 | 0.84 | P2RY1 (0.47) | KDRABL1NTRK1LCKFYN | |
| SCHEMBL3572047 | 0.84 | KDR (0.51) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293553-A1 | Diphenylurea Derivatives Useful As Potassium Channel Activators | NEUROSEARCH A/S (DK) | 2007-12-20 | — | — | US | claimed |
| US-20060178413-A1 | Diphenylurea derivatives and their use as chloride channel blockers | NEUSEARCH A/S (DK) | 2006-08-10 | — | — | US | claimed |
| US-7691891-B2 | Diphenylurea derivatives and their use as chloride channel blockers | NEUROSEARCH A/S (DK) | 2010-04-06 | — | — | US | disclosed |
| US-20070293553-A1 | Diphenylurea Derivatives Useful As Potassium Channel Activators | NEUROSEARCH A/S (DK) | 2007-12-20 | — | — | US | disclosed |
| US-20060178413-A1 | Diphenylurea derivatives and their use as chloride channel blockers | NEUSEARCH A/S (DK) | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293553-A1 | Diphenylurea Derivatives Useful As Potassium Channel Activators | KCNJ2, KCNH2, KCNH3 | CNR1 680/4885FABP4 1144/4885S1PR2 2257/4885 |
| US-20060178413-A1 | Diphenylurea derivatives and their use as chloride channel blockers | CLIC1, CLIC4, CLCN2 | CNR1 392/4885FABP4 2144/4885S1PR2 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.